BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim TW. EGFR status is not a reliable biomarker to select patients suitable for cetuximab-based therapy. Clin Colorectal Cancer 2014;13:3-4. [PMID: 24373734 DOI: 10.1016/j.clcc.2013.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 de Bree E, Rovers KP, Stamatiou D, Souglakos J, Michelakis D, de Hingh IH. The evolving management of small bowel adenocarcinoma. Acta Oncologica 2018;57:712-22. [DOI: 10.1080/0284186x.2018.1433321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
2 Khelwatty S, Essapen S, Bagwan I, Green M, Seddon A, Modjtahedi H. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget 2017;8:7666-77. [PMID: 28032593 DOI: 10.18632/oncotarget.13835] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]